A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Acerta Pharma BV
Mayo Clinic
Sellas Life Sciences Group
UNC Lineberger Comprehensive Cancer Center
University of Chicago
Mayo Clinic
Northside Hospital, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Amphivena Therapeutics, Inc.
University of Pittsburgh